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Abstract: The pathophysiological mechanisms of migraine transformation are debated. Modifications
of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA
(BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain
neurotransmitters release and oxidative stress products. Aims of our study were to investigate
differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein
Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic
migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical
modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found
higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM
group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP
(p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms
in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic
migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels
of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment
for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment.
Keywords: migraine; chronic migraine; medication overuse headache; BoNT/A; oxidative stress;
biomarkers
Key Contribution: (1) Imbalance of plasma oxidative stress biomarkers has been reported in chronic
migraine while BoNT/A treatment seems to reduce oxidative stress products. (2) In our study we
confirmed a different pattern of plasma oxidative stress biomarkers between controls and chronic
migraine patients. (3) BoNT/A treatment improved the levels of plasma oxidative stress biomarkers
in chronic migraine group during the follow-up.
1. Introduction
Migraine [1] is the most common neurological disorder, representing the third pathology for
human prevalence and the seventh most disabling disease [2,3]. Its life-time course is variable. Some
patients maintain a low frequency of attacks, while 3% transform into chronic migraineurs, with more
than 15 days per month of headache, often with medication overuse [4,5]. OnabotulintoxinA (BoNT/A)
was approved for chronic migraine treatment after two phase III studies demonstrated its efficacy as
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prophylaxis [6,7], even in the presence of painkiller abuse [8]. BoNT/A could hamper the release of
substance P, calcitonin gene-related peptide (CGRP), and glutamate by the trigeminal/cervical nervous
fibers, thus decreasing the liberation of pain neurotransmitters as well as oxidative stress products [9–11].
Further evidence supports the hypothesis of retrograde transport of BoNT/A along axons that may
attenuate the central sensitization in the trigeminal ganglia and nucleus [12–14]. Although the
pathophysiological mechanisms underlying migraine attacks and migraine transformation from an
episodic to a chronic pattern are not fully understood, several data suggest that oxidative mitochondrial
metabolism is altered in migraine patients. Modified levels of plasma oxidative stress biomarkers
have been described in studies on either chronic migraine or neuropathic pain associated with central
sensitization [15,16]. Literature data regarding oxidative stress biomarkers specific for migraine are
heterogeneous. However, previous investigations reported that plasma levels of Advanced Oxidation
Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), and Thiolic Groups (SH) showed
significant differences between migraine patients and healthy controls (HC) [15].
Aims of our study are: (a) to investigate differences in the levels of the plasmatic oxidative
stress biomarkers AOPP, FRAP, and SH comparing a population of chronic migraineurs (CM) with a
group of HC; (b) to measure possible modifications of plasmatic concentrations of oxidative stress
biomarkers in CM after a six-month period of treatment with BoNT/A; and (c) to measure possible
modifications of migraine clinical features and outcomes after BoNT/A treatment, using appropriate
and validated scales.
2. Results
Twenty-seven patients with a clinical diagnosis of chronic migraine with medication overuse and
27 HC matched for age and sex were recruited. Demographic data and results of biomarkers blood
testing at baseline visit in the two groups are reported in Table 1. Significant differences between the
two groups were found at T0 regarding plasmatic levels of AOPP (p < 0.001), SH (p < 0.001) and FRAP
(p = 0.005). Clinical significant differences (p < 0.001) in the CM group were recorded at T1, with
reduction of headache frequency, consumption of symptomatic drugs, FSS score, VNS score, HIT-6
score, ASC-12 score, GAD-7 score; no significant differences were obtained regarding the PHQ-9 score.
Analysis of biomarker levels at T1 showed a significant increase of FRAP (p < 0.001) and SH (p = 0.023)
and a significant reduction of AOPP (p < 0.001). Detailed results of clinical scales and biological
assessments in the migraine group at T0 and T1 are reported in Tables 2 and 3.
Table 1. Demographic descriptors and biomarkers values of oxidative stress between HC and CM
groups at T0. Quantitative variables are expressed in terms of median and interquartile, the categorical
variables are expressed as a percentage.
Variable HC Group CM Group p-Value
Sex F/M (percentage) F = 21 (77.8%)
M = 6 (22.2%)
F = 21 (77.8%)
M = 6 (22.2%)
NS
Age (years) (Median, IQ) 54 (45–59) 53 (44–58) NS
AOPP nmol/L (Median, IQ) 119.1 (101.3–189.2) 258.0 * (192.5–373.1) <0.001
FRAP mmol/L (Median, IQ) 0.817 * (0.646–0.861) 0.612 (0.559–0.557) =0.005
SH µmol/L (Median, IQ) 0.456 * (0.395–0.549) 0.297 (0.237–0.381) <0.001
AOPP: advanced oxidation protein products; CM: chronic migraine; FRAP: ferric-reducing antioxidant power; HC:
Healthy Controls; SH: Thiolic Groups; IQ: interquartile range; NS: not statistically significant. *: significantly higher
values (p < 0.05).
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Table 2. Comparison between plasmatic values of oxidative stress biomarkers (AOPP, FRAP, and SH)
at T0 (baseline) and T1 (6-month follow-up) in the CM group.
Variable T0 T1 p-Value
AOPP nmol/L (Median, IQ) 258.0 (192.5–373.1) * 202.8 (87.3–253.3) <0.001
FRAP mmol/L (Median, IQ) 0.612 (0.559–0.557) 0.752 (0.568–0.918) * <0.001
SH µmol/L (Median, IQ) 0.297 (0.237–0.381) 0.368 (0.272–0.460) * =0.023
AOPP: advanced oxidation protein products; FRAP: ferric-reducing antioxidant power; IQ: interquartile range; HC:
Healthy Controls; CM: chronic migraine; SH: Thiolic Groups. *: significantly higher values (p < 0.05).
Table 3. Comparison between T0 and T1 regarding clinical features and scores obtained for each
migraine scale in the CM group.
Variable T0 Median (IQ) T1 Median (IQ) p-Value
Headache frequency (days/month) 25.0 * (20.0–30.0) 15.5 (11.5–25.0) < 0.001
Symptomatics/per month 25.0 * (20.0–30.0) 15.0 (10.0–25.0) < 0.001
FSS 47.0 * (38.0–53.0) 28.0 (27.0–32.0) < 0.001
VNS 8.0 * (8.0–10.0) 5.0 (5.0–7.0) < 0.001
HIT-6 66.0 * (64.0–73.0) 56.0 (51.0–63.0) < 0.001
ASC-12 5.0 * (2.0–12.0) 2.0 (0–6.0) < 0.001
GAD 7 10.0 * (7.0–16.0) 9.0 (6.0–13.0) < 0.001
PHQ 9 9.0 (6.0–15.0) 9.0 (6.0–14.0) NS
ASC-12: Allodynia Symptoms Checklist 12, FSS: Fatigue Severity Scale; GAD–7: Generalized Anxiety Disorder;
HIT-6: Headache Impact Test; IQ: interquartile range; PHQ–9: Patient Health Questionnaire; VNS: Verbal Numeric
Scale; NS: not statistically significant. *: significantly higher values (p < 0.05).
A comparison between plasmatic biomarkers levels measured in the CM group at T1 and values
obtained in HC at T0 did not detect significant differences regarding AOPP and FRAP, whereas a
significant difference was observed in SH levels (p = 0.01); detailed results are reported in Table 4.
Table 4. Comparison between plasmatic values of oxidative stress biomarkers (AOPP, FRAP and SH)
in HC Group and CM group at T1.
Variable HC Group CM Group T1 p-Value
AOPP nmol/L (Median, IQ) 119.1 (101.3–189.2) 202.8 (87.3–253.3) NS
FRAP mmol/L (Median, IQ) 0.817 (0.646–0.861) 0.752 (0.568–0.918) NS
SH µmol/L (Median, IQ) 0.456 * (0.395–0.549) 0.368 (0.272–0.460) = 0.01
AOPP: advanced oxidation protein products; FRAP: ferric-reducing antioxidant power; IQ: interquartile range; HC:
Healthy Controls; CM: chronic migraine; SH: Thiolic Groups. *: significantly higher values (p < 0.05).
3. Discussion
The results of the present study confirm previous observations of a close relationship between
migraine and oxidative stress [15,17,18]. Impairment of antioxidant mechanisms in the group of
migraine patients was measured employing the plasmatic oxidative stress biomarkers AOPP, FRAP,
and SH. In a previous study on patients with a clinical diagnosis of chronic migraine with medication
overuse, a significant reduction of FRAP and SH levels was reported compared to HC, whereas
evaluation AOPP levels failed to demonstrate significant differences [15]. At the baseline evaluation
we obtained significantly higher values of AOPP (p < 0.001) and lower values of SH (p < 0.001) and
FRAP (p = 0.005) in the CM group, with respect to HC.
The complex mechanisms of action of BoNT/A on nociception include the block of CGRP release
with consequent effects on peripheral sensitization in response to inflammation [19–23]. In order to
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evaluate possible modifications of plasmatic oxidative stress biomarkers after exposure to BoNT/A
in the CM group we measured the levels of selected biomarkers after 6 months of treatment (T1).
We detected a significant reduction of AOPP (p < 0.001) and increase of FRAP (p < 0.001) and SH
(p = 0.023) with respect to baseline. Overall, according to our results, BoNT/A treatment seems to
improve the functioning of antioxidant mechanisms in CM patients, with normalization of AOPP
and FRAP levels after the 6-month observational period compared to HC. Median values of the SH
biomarker, however, remained significantly lower of those measured in the HC group.
A further objective of the study was to investigate the effect of BoNT/A on clinical features,
measured by means of specific scales and disease descriptors, including pain intensity (VNS), disability
(HIT-6), presence of fatigue (FSS) or anxiety (GAD-7), drug consumption and headache days/month.
As expected, BoNT/A treatment improved migraine symptoms in the CM group with a significant
reduction (p < 0.001) of the scores of all parameters considered at the T1 evaluation, except for the
PHQ–9 questionnaire [24].
The prospective evaluation of allodynia using the ASC-12 after the 6-month treatment with
BoNT/A showed a significant reduction of the score (p < 0.001) from a median value of 5 at T0 (2.0-12.0),
to a median value of 2 at T1 (0–6.0). Repeated episodes of migraine have a cumulative effect in inducing
the development of central sensitization phenomena of the trigeminus-vascular system, which seems
to exert its clinical expression in allodynia [25,26].
The results of the present study confirm previous reports of imbalanced antioxidant mechanisms
in chronic migraine and medication overuse headache, with a reduction of antioxidant capacities in
patients compared to controls [15–18]. BoNT/A treatment confirms its role as an effective prophylactic
treatment for chronic migraine, not only reducing the number of days per month and drug consumption
but also improving associated symptoms, particularly ictal allodynia. According to our data, BoNT/A
treatment outcome could have indirect antioxidant properties, improving the levels of plasma oxidative
stress biomarkers. More interesting, a BoNT/A direct antioxidant property could be speculated. Animal
models of BoNT/A injection, in fact, demonstrated a reduction of intracellular accumulation of reactive
oxygen species (ROS) and the activation of chemoprotective and antioxidant genes such as glutathione
S-transferase [27,28]. Comparative studies with other molecules approved for chronic migraine and
medication overuse headache are mandatory to corroborate this hypothesis.
However, our study needs some caveats. First, the sample size is relatively small. As a
consequence, sub-population analyses, such as BoNT/A responders versus non-responders or triptan
overuse versus nonsteroidal anti-inflammatory drugs (NSAIDs) overuse are not possible. The group of
episodic migraineurs could not be included in the treatment, as BoNT/A is not approved for episodic
migraine [6,7]. The respective weight of chronic migraine and medication overuse to oxidative stress
impairment could not be assessed, because all patients have both diagnoses. The role of triptans or
NSAIDs consumption on the described reduced antioxidant activity in those patients [15], as well
as chronic migraine per se, could not be investigated in this clinical setting. Moreover, we did not
search for potential sex differences. Finally, we did not include a group of migraineurs with aura and
the follow-up is relatively short compared to the natural history of the disease. Additionally, plasma
biomarkers level of episodic migraineurs were not collected, thus, a comparison between antioxidant
levels in episodic and chronic patients could not be performed.
Further studies will be necessary to understand the pathophysiological mechanisms leading
to chronic migraine and to determine the effective relationship between migraine and antioxidant
mechanisms modifications, clarifying the possible role of BoNT/A in this field.
4. Materials and Methods
4.1. Study Population
A prospective study was carried out. We recruited consecutive outpatients of the Headache
Centre of the University of Pisa, from October 2017 to March 2019, with the following enlisted inclusion
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criteria (IC) and exclusion criteria (EC). IC: (1) age ≥ 18 years; (2) normal neurologic evaluation;
(3) brain MRI examination without pathological findings; and (4) absence of migraine preventive
treatment for at least 3 months before study inclusion; (5) patient fulfilling both chronic migraine and
medication-overuse headache according to ICHD-3 diagnostic criteria [1]; EC: (1) comorbid medical
disorders and treatments for chronic systemic diseases; (2) patients with headache attacks fulfilling
the criteria for Migraine with aura, according to ICHD-3. The second EC was determined to obtain
a more homogeneous sample and only patients affected by migraine without aura were included,
thus excluding subjects presenting migraine with aura ab initio. The overused medications were also
limited to NSAIDs and triptans. As far as controls are concerned, healthy subjects were recruited
among patients’ family members, not genetically related, and hospital workers. Individuals with
headache history, as assessed through a clinical interview, were excluded; additionally, subjects with a
positive history of medical disorders or with chronic medication use were excluded from the present
study. All patients were BoNT/A-naïve and were not enrolled in previous clinical studies on migraine.
This study has been performed in accordance with the Declaration of Helsinki and it was approved by
the local ethics committee (Comitato Etico Area Vasta Nord Ovest – CEAVNO, Sezione Autonoma del
Comitato Etico Regionale per la Sperimentazione Clinica, Via Roma 67, 56126, Pisa, Italy). All patients
provided valid written, informed consent before study inclusion. The approval code and date: ID14518
in 19 February 2019.
4.2. Clinical Evaluation
Patients underwent three visits at intervals of three months: baseline (T0), 3-month, and 6-month
(T1) evaluation. At the end of each visit (T0, 3-month, and T1) BoNT/A was administered according to
PREEMPT protocol [6,7].
Clinical features of migraine were measured by means of appropriate scales [29,30] during T0 and
T1 visits: Verbal Numeric Scale (VNS) to calculate pain intensity, Headache Impact Test (HIT-6) for the
assessment of related disability, Fatigue Severity Scale (FSS) that measures fatigue-associated disability,
Allodynia Symptoms Check-list 12 (ASC-12) for a specific measure of ictal allodynia, Generalized
Anxiety disorder (GAD – 7) and Patient Health Questionnaire (PHQ – 9), indicators of anxiety and
mood disorders. Clinical assessment during 3-month visit was conducted with an interview without
the abovementioned questionnaires.
The patients were asked to record headache frequency on their diary before T0 and T1 visits,
to measure the number of headache days per month.
4.3. Biochemical Evaluation
Blood samples were collected during T0 and T1 visit for CM group and only at T0 for the HC
group. Blood venous samples were collected in the early morning, shortly after a light breakfast.
Samples were centrifuged at 2500× g for 10 min at 4 ◦C within 2 h after collection and analyzed within
1 month after collection. Plasmatic levels of AOPP, FRAP, and SH were determined in patients and HC
as described elsewhere [15]. All procedures were performed at our Neurology Unit Laboratory.
AOPP are markers of oxidative damage to proteins and include reaction products of the
plasma proteins produced by the myeloperoxidase enzyme. Results were expressed as nmol/mL of
chloramine equivalents.
FRAP is a biomarker that estimates the antioxidant power and measures non-enzymatic antioxidant
properties. The data were expressed as mmol/L.
A further component of plasma antioxidant barrier is represented by total thiol groups.
The sulfhydryl groups (SH) of plasma molecules can oppose the propagation of oxidative processes.
Data were expressed as mol/L.
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4.4. Statistical Analysis
The quantitative variables were not normally distributed. The continuous variables are expressed
as Average, Standard Deviation, Median and Interquartile Interval (IQ). The categorical variables are
expressed as frequency percentages. The comparison between non-parametric quantitative variables
was performed employing the Wilcoxon test to compare the difference at T0 and T1 of the quantitative
variables within the migraine population. Mann -Whitney U test was used to compare the difference of
the quantitative variables between the migraineurs and controls. The comparison between categorical
dichotomous variables was performed by the chi-square test with continuity correction. SPSS version
24.0 for Windows was used for statistical analyses.
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